<DOC>
	<DOCNO>NCT00797472</DOCNO>
	<brief_summary>120 subject Hodgkin 's disease randomly divide two group : Group I receive R-mabHD Group II receive combination Adriamycin , Bleomycin , Vinblastine Dacarbazine . R-mabHD give week eight week row . The ABVD combination give every week 12 treatment . The hypothesis intervention R-mabHD lead quicker remission Hodgkin 's disease intervention combination ABVD .</brief_summary>
	<brief_title>Study Comparing R-mabHD Combination ABVD Hodgkin 's Disease</brief_title>
	<detailed_description>The primary objective compare efficacy R-mabHD combination therapy Adriamycin , Bleomycin , Vinblastine Dacarbazine ( ABVD ) bring remission Hodgkin 's lymphoma reduction tumor size . Primary Study Endpoint : Primary efficacy criterion percentage patient achieve functional score 1 . Efficacy evaluation base assessment functional score . At end six month , functional assessment tumor undertaken record score follow : Score 1 : &gt; /= 50 % reduction size tumor Score 2 : &lt; 50 % reduction size tumor . Secondary Study Endpoint : Additional secondary endpoint average time achieve 50 % reduction size tumor . 120 subject Hodgkin 's Disease divide randomly two group . 60 subject ( Group I ) receive R-mabHD intravenous infusion dose 375mg/m2 week eight week row . The half ( Group II ) receive combination intravenous Adriamycin , Bleomycin , Vinblastine Dacarbazine every week 12 treatment . Enrollment period three year subject gender accept . Subjects age 18 65 . No healthy volunteer accept . Females nurse baby pregnant exclude study . Subjects evaluate every month first six month one year eighteen month baseline visit one .</detailed_description>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1 . Must sign inform consent form 2 . Must histologically proven diagnosis Hodgkin 's lymphoma 3 . Both gender age 18 65 4 . Must adequate bone marrow reserve ( ANC.1500/mm3 , Platelet &gt; 50,000/mm3 ) 5 . Must bidimensionally measureable disease 6 . LVEF &gt; 50 % echocardiogram 7 . Serum creatinine upto one fold 8 . Serum bilirubin upto one fold 9 . Hepatitis B surface antigen negative 10 . Hodgkin 's Disease patient relapse radiation therapy alone surgical treatment alone , previously untreated patient stage II bulky , III IV . 1 . HIV positive 2 . Pregnant woman woman child bear age practise adequate contraception 3 . Severe pulmonary disease include COPD asthma 4 . Evidence malignancy except superficial nonmelanoma skin carcinoma carcinoma situ cervix 5 . Nursing mother 6 . Uncontrolled active infection 7. concurrent prednisone systemic steroid therapy 8 . Less 4 week since prior radiotherapy 9 . Less 30 day since prior investigational therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Hodgkin 's Lymphoma</keyword>
	<keyword>R-mabHD</keyword>
	<keyword>ABVD treatment</keyword>
	<keyword>Hodgkin 's Disease</keyword>
</DOC>